Filtered By:
Cancer: Breast Cancer
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 411 results found since Jan 2013.

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

The effect of butylphthalide on improving the neurological function of patients with acute anterior circulation cerebral infarction after mechanical thrombectomy
Medicine (Baltimore). 2023 Aug 25;102(34):e34616. doi: 10.1097/MD.0000000000034616.ABSTRACTButylphthalide can improve blood circulation in patients with acute cerebral infarction. Complement 3a receptor 1 (C3aR1) is involved in the regulation of innate immune response and pathogen monitoring, which is closely related to the pathophysiological processes of breast cancer, neurogenesis and lipid catabolism. Our study explored the therapeutic effect of butylphthalide on improving the neurological function of patients with acute anterior circulation cerebral infarction after mechanical thrombectomy, and evaluated the correlatio...
Source: Cancer Control - September 1, 2023 Category: Cancer & Oncology Authors: Xinghua Wang Xinchi Luan Zhigang Yang Source Type: research

< em > ABCG2 < /em > Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
CONCLUSION: The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.PMID:37641689 | PMC:PMC10460569 | DOI:10.2147/DDDT.S417096
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Hamin Kim Tae-Jin Song Jeong Yee Dong-Hyeok Kim Junbeom Park Hye Sun Gwak Source Type: research

Where You Live Can Shape How Alzheimer ’ s Affects You
The FDA in mid-July for the first time ever approved an Alzheimer’s drug, Leqembi. The annual price-tag will run patients $26,500. The same week, the Alzheimer’s Association for the first time ever released county-level data to identify which communities are most struggling with the disease. 6.7 million Americans live with Alzheimer’s disease and 134,000 of them will die because of it each year. We’ve known these aggregate numbers for a while now, but with new data and new drugs, healthcare specialists can now better target attention and resources. [time-brightcove not-tgx=”true”] ...
Source: TIME: Health - August 7, 2023 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news

Social Determinants of Health and Racial Disparities in Cardiac Events in Breast Cancer
CONCLUSIONS: Neighborhood and built environment variables are the most important SDOH predictors for 2-year MACE, and NHB patients were more likely to have unfavorable SDOH conditions. This finding reinforces that race is a social construct.PMID:37433439 | DOI:10.6004/jnccn.2023.7023
Source: Cancer Control - July 11, 2023 Category: Cancer & Oncology Authors: Nickolas Stabellini Mantas Dmukauskas Marcio S Bittencourt Jennifer Cullen Amie J Barda Justin X Moore Susan Dent Husam Abdel-Qadir Aniket A Kawatkar Ambarish Pandey John Shanahan Jill S Barnholtz-Sloan Kristin A Waite Alberto J Montero Avirup Guha Source Type: research